

LESLIE J KLAFF, MD, PHD, FRCP, FACE

800 SW 39th St, Ste 110, Renton, WA · 425-251-1720 (Office), 425-970-1304 (Direct)
LJKlaff@Rainier-Research.com

Founded in 1991, Rainier Clinical Research Center is a private, dedicated, multi-specialty investigative site conducting Phase I-IV clinical trials for drugs and devices. We have successfully completed 600+ studies with 200+ sponsors and contract research organizations.

EXPERIENCE

1992 - PRESENT

MEDICAL DIRECTOR, RAINIER CRC, LLC

1989 – 1998

PARTNER, RAINIER INTERNAL MEDICINE, RENTON WA

1998 - 2006

PARTNER, SOUTHLAKE CLINIC (PREVIOUSLY VALLEY INTERNAL MEDICINE)

EDUCATION

1971

M.B.B.CH. (MD EQUIVALENT), UNIVERSITY OF WITWATERSRAND MEDICAL SCHOOL

1983

PH.D., UNIVERSITY OF CAPE TOWN

ADDITIONAL DEGREES

1975

M.R.C.P. (MEMBER OF THE ROYAL COLLEGE OF PHYSICIANS), LONDON, ENGLAND

1990

F.R.C.P. (FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS), EDINBURGH SCOTLAND

2003

F.A.C.E. (FELLOW OF THE AMERICAN COLLEGE OF ENDOCRINOLOGY)

Signature: _____

Date: _____

POSTGRADUATE TRAINING

1972 – 1974

ROTATING INTERNSHIP (INTERNAL MEDICINE, SURGERY AND PEDIATRICS), JOHANNESBURG
GENERAL HOSPITAL

1975

SENIOR HOUSE OFFICER, ROYAL NORTHERN HOSPITAL

1976 – 1977

REGISTRAR, INTERNAL MEDICINE, UNIVERSITY OF CAPE TOWN AND GROOTE SCHUUR HOSPITAL

1977 – 1979

RESEARCH FELLOW, DIABETES AND ENDOCRINE RESEARCH GROUP, UNIVERSITY OF CAPE TOWN

1979 – 1980

SENIOR REGISTRAR, ENDOCRINOLOGY AND METABOLISM, GROOTE SCHUUR HOSPITAL

BOARD CERTIFICATIONS

1980

REGISTERED AS SPECIALIST IN INTERNAL MEDICINE WITH SOUTH AFRICAN MEDICAL AND DENTAL
COUNCIL

1985

AMERICAN BOARD OF INTERNAL MEDICINE

1987

AMERICAN BOARD OF ENDOCRINOLOGY AND METABOLISM

LICENSURE TO PRACTICE

1971

SOUTH AFRICA

1973

UNITED KINGDOM

1982

STATE OF WASHINGTON (LICENSE NUMBER MD00021403)

HOSPITAL POSITIONS

1980 – 1982

SPECIALIST PHYSICIAN, GROOTE SCHUUR HOSPITAL, CAPE TOWN, RSA

1982 – 1983

SENIOR SPECIALIST PHYSICIAN, GROOTE SCHUUR HOSPITAL, CAPE TOWN, RSA

1983 – 1989

ATTENDING PHYSICIAN, PACIFIC MEDICAL CENTER, SEATTLE, WA

FACULTY POSITIONS

1980 – 1982

LECTURER, INTERNAL MEDICINE & ENDOCRINOLOGY, UNIVERSITY OF CAPE TOWN MEDICAL SCHOOL

1982 – 1983

SENIOR LECTURER, INTERNAL MEDICINE & ENDOCRINOLOGY, UNIVERSITY OF CAPE TOWN MEDICAL SCHOOL

1982 – 1983

ACTING HEAD, ENDOCRINE AND DIABETES RADIOIMMUNOASSAY LABORATORY, UNIVERSITY OF CAPE TOWN

1983 – 1989

ASSISTANT PROFESSOR OF MEDICINE, DEPARTMENT OF ENDOCRINOLOGY, METABOLISM, AND NUTRITION, UNIVERSITY OF WASHINGTON

1987 – 1989

DIRECTOR, RADIOIMMUNOASSAY CORE, DIABETES ENDOCRINOLOGY RESEARCH CENTER, UNIVERSITY OF WASHINGTON

1989

ASSOCIATE PROFESSOR OF MEDICINE, DEPARTMENT OF ENDOCRINOLOGY, METABOLISM, AND NUTRITION, UNIVERSITY OF WASHINGTON

1989 – 2004

CLINICAL ASSOCIATE PROFESSOR OF MEDICINE, DEPARTMENT OF ENDOCRINOLOGY, METABOLISM, AND NUTRITION, UNIVERSITY OF WASHINGTON

2004

CLINICAL PROFESSOR OF MEDICINE, DEPARTMENT OF ENDOCRINOLOGY, METABOLISM, AND NUTRITION, UNIVERSITY OF WASHINGTON

2019

EMERITUS CLINICAL PROFESSOR OF MEDICINE, DEPARTMENT OF ENDOCRINOLOGY, METABOLISM, AND NUTRITION, UNIVERSITY OF WASHINGTON

PROFESSIONAL ORGANIZATION MEMBERSHIP

1972 – 1973

MEDICAL ASSOCIATION OF SOUTH AFRICA

1979 – 1983

BOARD MEMBER, SOCIETY FOR ENDOCRINOLOGY, METABOLISM, AND DIABETES OF SOUTHERN AFRICA

1982

AMERICAN DIABETES ASSOCIATION

1984 – 1989

AMERICAN FEDERATION FOR CLINICAL RESEARCH

1984

ENDOCRINE SOCIETY

HONORS, AWARDS & LEADERSHIP

1980

BERNARD PIMSTONE MEMORIAL AWARD FOR BEST YOUNG INVESTIGATOR

NOV 1982

ORGANIZING COMMITTEE FOR SYMPOSIUM ON CURRENT TRENDS IN DIABETES MELLITUS
(SATELLITE MEETING IN CAPE TOWN TO 11TH CONGRESS OF INTERNATIONAL DIABETES
FEDERATION IN NAIROBI)

1985 – 1991

BOARD MEMBER, AMERICAN DIABETES ASSOCIATION, WASHINGTON AFFILIATE

1985 – 1987

CO-CHAIRMAN, PROFESSIONAL EDUCATION COMMITTEE, AMERICAN DIABETES ASSOCIATION,
WASHINGTON AFFILIATE

1985 – 1989

PHARMACY AND THERAPEUTICS COMMITTEE, PACIFIC MEDICAL CENTER

1987 – 1989

RESEARCH COMMITTEE, PACIFIC MEDICAL CENTER

1988 – 1990

PEER REVIEW COMMITTEE, AMERICAN DIABETES ASSOCIATION, WASHINGTON AFFILIATE

1992 – 2002

CME COMMITTEE, VALLEY MEDICAL CENTER

1998 – 2008

ENDOCRINE DAYS ORGANIZING COMMITTEE

CLINICAL RESEARCH PROJECTS

1983 – 1989

DIABETES CONTROL AND COMPLICATIONS TRIAL, CO-INVESTIGATOR, NATIONAL INSTITUTES OF
HEALTH

1983 – 1989

INVESTIGATIONS OF THE ETIOLOGY OF TYPE I DIABETES, CO-INVESTIGATOR, NATIONAL INSTITUTE
OF HEALTH

1992 – PRESENT

RAINIER CLINICAL RESEARCH CENTER, PRINCIPAL INVESTIGATOR OR SUB-INVESTIGATOR ON
OVER 600 CLINICAL TRIALS PHASE I-IV

BIBLIOGRAPHY

1. Klaff LJ, Levin PJ, Potgieter PD, Losman JG, Nochomovitz LE, and Ferguson AD: Treatment of paraquat poisoning with the membrane oxygenator: a case report. S Afr Med J 51:203-205, 1977.
2. Klaff LJ, Vinik AI, Berelowitz M and Jackson WPU: Circulating antibodies in diabetics treated with monocomponent and conventional insulin. S Afr Med J 54:149-153, 1978.
3. Levin PJ, Klaff LJ, Rose AG, and Ferguson AD: Pulmonary effects of contact exposure to paraquat: a clinical and epidemiological study. Thorax 34:150-160, 1979.

4. **Klauff LJ**, Vinik AI, Jackson WPU, Malan E, Kernoff L, and Jacobs P: A comparison of the effects of the sulfonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet functions. *S Afr Med J* 56:247-250, 1979.
5. Coetzee J, **Klauff LJ**, and Epstein S: The measurement of human serum parathyroid hormone in disorders of calcium metabolism and during administration of certain gut hormones. *S Afr Med J* 57:165-170, 1980.
6. Levitt NS, Vinik AI, Sive AA, **Klauff LJ**, and Phillips C: A double-blind cross-over trial of synthetic gonadotrophin-releasing hormone (LHRH) in impotent male diabetics. *S Afr Med J* 57:701-704, 1980.
7. **Klauff LJ**, Hudson A, Sheppard M, and Tyler M: In vitro release of cholecystokinin octapeptide-like immuno-reactivity from rat brain synaptosomes. *S Afr Med J* 59:158-160, 1981.
8. **Klauff LJ**, Kernoff L, Vinik AI, Jackson WPU, and Jacobs P: Sulphonylureas and platelet function. *American J Med* 70:627-730, 1981.
9. Wright JP, Young GO, **Klauff LJ**, Weers LA, Price SK, and Marks IN: Gastric mucosal prostaglandin E levels in patients with gastric ulcer disease and carcinoma. *Gastroenterology* 82:263-267, 1982.
10. Millar RP, **Klauff LJ**, Barron J, Levitt NS, and Ling N: Somatostatin-28 inhibits Gn-RH-stimulated gonadotrophin secretion in man. *Clin Endocrinol* 17:103-107, 1982.
11. **Klauff LJ**, Hudson AM, Paul M, and Millar RP: A method for studying synaptosomal release of neurotransmitter candidates as evaluated by studies on cortical cholecystokinin octapeptide release. *Peptides* 3:155-161, 1982.
12. **Klauff LJ**, Barron JL, Levitt NS, Millar RP, and Ling N: Somatostatin-28 inhibits thyroid-stimulating hormone release in man. *S Afr Med J* 62:929-930, 1982.
13. Millar RP, **Klauff LJ**, Barron JL, Levitt NS, and Ling N: Somatostatin-28 and somatostatin-14 suppression of arginine-, insulin-, and TRH-stimulated GH & prolactin secretion in man. *Clin Endocrinol* 18:277-285, 1983.
14. Mee AS, **Klauff LJ**, Girdwood A, Paul M, Tyler M, and Marks IS: A comparative study of pancreatic polypeptide secretion endocrine and exocrine function and structural damage in chronic alcohol induced pancreatitis (CAIP). *Gut* 24:642-647, 1983.
15. Maze SS, **Klauff LJ**, and Yach D: Syndrome of inappropriate antidiuretic hormone secretion in association with herpes zoster of the chest wall. *S Afr Med J* 63:735-736, 1983.
16. **Klauff LJ**, Barron JL, Levitt NS, Ling N, and Millar RP: Inhibition of pancreatic hormone secretion by somatostatin-28 and somatostatin-14 in man. *Acta Endocrinologica* 104:91-95, 1983.
17. Barron JL, **Klauff LJ**, Levitt NS, Ling N, and Millar RP: Arginine hydrochloride stimulation of serum potassium and aldosterone is enhanced by somatostatin-28. *Acta Endocrinologica* 105:407-410, 1984.
18. Koeslag JH, Levinrad LI, **Klauff LJ**: Pancreatic polypeptide response to exercise: Effect of alanine and glucose ingestion in carbohydrate-starved athletes. *S Afr Med J* 67:884-887, 1985.
19. Roost R, Wright JP, Young GO, Lipshitz EM, **Klauff LJ**, Isaacs S, and Marks IN: The effect of aspirin and anti-ulcer drugs on gastric mucosal prostaglandin E. *S Afr Med J* 70:594-597, 1986
20. Johnston C, Raghu P, McCulloch DK, Beard JC, Ward WK, **Klauff LJ**, McKnight B, Bergman RN, Palmer JP: Beta cell function and insulin sensitivity in non-diabetic HLA identical siblings of insulin dependent diabetics. *Diabetes* 36:829-837, 1987.
21. **Klauff LJ** and Taborsky GJ Jr: Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. *Diabetes* 36:592-596, 1987.
22. **Klauff LJ**, Tamborlane WV, Cleary PA, Steffes MW, and Becker DJ: For the DCCT Research Group: Effects of age, duration and treatment of IDDM on residual B-cell function: Observations during eligibility testing for the diabetes control and complications trial (DCCT). *J Clin Endocrinol Metab* 65:30-36, 1987.
23. **Klauff LJ** and Taborsky GJ Jr: The role of pancreatic somatostatin in determining the glucagon response to arginine and morphine. *Am J Physiol* 252:E751-E755, 1987.
24. Dent DM, Miller JL, **Klauff LJ**, and Barron J: The incidence and causes of hypercalcaemia. *Postgrad Med J* 63:745-750, 1987.
25. McCulloch DM, Raghu PK, Johnston C, **Klauff LJ**, Kahn SE, Beard JC, Ward WK, Benson EA, Koerker DJ, Bergman RN, Palmer JP: Defects in beta cell function and insulin sensitivity in normoglycemic

- streptozocin treated baboons: a model of preclinical insulin dependent diabetes. *J Clin Endocrinol Metab* 67:785-792, 1988.
26. Sutton M, **Klauff** LJ, Asplin CM, Clemons P, Tatpati O, Lyen K, Raghu P, Baker L, Guthrie R, Sperling M, and Palmer JP: Insulin autoantibodies at diagnosis of insulin dependent diabetes--effect on the antibody response to insulin treatment. *Metabolism* 37:1005-1007, 1988.
 27. **Klauff** LJ, Dunning BE, and Taborsky GJ Jr: Somatostatin-28 does not regulate islet function in the dog. *Endocrinology* 123:2668-2674, 1988.
 28. Willcox PA, Immelman EJ, Barron JL, **Klauff** LJ, Harries-Jones EP, Hainsworth M, and Millar RP: Pancreatic somatostatinoma: presentation with recurrent episodes of severe hyperglycemia and ketoacidosis. *Quart J Med* 255:559-571, 1988.
 29. McCulloch DK, Raghu PK, Koerker DJ, Palmer JP, and **Klauff** LJ: Responses of the pancreatic A-cell during hypoglycemia hyperglycemia are dependent on the B-cell. *Metabolism* 38:702-709, 1989.
 30. McCulloch DK, **Klauff** LJ, Kahn SE, Schoenfeld SL, Greenbaum CJ, Mauseth RS, Benson EA, Nepom GT, Shewey L, and Palmer JP: Nonprogression of subclinical B-cell dysfunction among first-degree relatives of IDDM patients: 5-year follow-up of Seattle study. *Diabetes* 39:549-556, 1990.
 31. Markholst H, **Klauff** LJ, Kloppel G, Lernmark A, Mordes JP, and Palmer J: Lack of systemically found insulin autoantibodies in spontaneously diabetic BB rats. *Diabetes* 39:720-727, 1990.
 32. Kahn SE, **Klauff** LJ, Schwartz MW, Beard JC, Bergman RN, Taborsky GJ Jr, and Porte D Jr: Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. *J Clin Endocrinol Metab* 71:797-805, 1990
 33. Greenbaum CJ, Havel PJ, Taborsky GJ Jr, and **Klauff** LJ: Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. *J Clin Invest* 88:767-773, 1991.
 34. Hegewald MJ, Schoenfeld SL, McCulloch DK, Greenbaum CJ, **Klauff** LJ, and Palmer JP: Increased specificity and sensitivity of insulin antibody measurements in autoimmune thyroid disease and type I diabetes. *J Immunol Meth* 154: 61-68, 1992.
 35. Kolterman OG, Schwartz S, Corder C, Levy B, **Klauff** LJ, Peterson J, Gottlieb A: Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. *Diabetologia* 39:492-499, 1996.
 36. Raskin P, **Klauff** L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. *Diabetes Care* 23:1666-1671, 2000.
 37. Ehlers MR, **Klauff** LJ, D'Alessio DA, Brazg R, Kay HD, Harley R, Mathison A, Schneider R: Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. *Horm Metab Res* 35:611-6, 2003.
 38. Raskin P, **Klauff** L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. *Diabetes Care* 26: 2063-8, 2003.
 39. Warren ML, Conway MJ, **Klauff** LJ, Rosenstock J, Allen E: Postprandial vs preprandial dosing of biphasic insulin aspart in elderly patients with type 2 diabetes. *Diabetes Res and Clin Practice* 66:23-9, 2004.
 40. Amiel SA, Heller SR, Macdonald IA, Schwartz SL, **Klauff** LJ, Ruggles JA, Weyer C, Kolterman OG, Maggs DG. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. *Diabetes Obes Metab*. 7:504-16. 2005
 41. Thisted RA, **Klauff** L, Schwartz SL, Wymer JP, Culligan NW, Gerard G, Pope LE, Berg JE. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. *Clin Ther*. 28:1607-18. 2006
 42. Wolfenbuttel BH, **Klauff** LJ, Bhushan R, Fahrback JL, Jiang H, Martin S. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. *Diabet Med*. 11:1147-55. 2009

43. Rosenstock J, **Klauff** LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Prediabetes. *Diabetes Care*. 33:1173-5. 2010
44. Hirsch LJ, Gibney MA, Albanese J, Qu S, Klassker-Taub K, **Klauff** LJ, Bailery TS. Comparative glycemic control, safety and patient ratings for a new 4mm x 32G insulin pen needle in adults with diabetes. *Curr Med Res Opin*. 26:1531-41. 2010
45. Jarrahan C, Zehrung D, Saxon E, Griswold E, **Klauff** LJ. Clinical performance and safety of the ID adapter, a prototype intradermal delivery technology for vaccines, drugs, and diagnostic tests. *Procedia in Vaccinology*; 6:125-133. 2012
46. Brazg, RL, **Klauff**, LJ, Parkin, CG. Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers. *J Diabetes Sci Technol* 7:144-152, 2013
47. Garg SK, Moser EG, Bode BW, **Klauff** LJ, Hiatt WR, Beatson C, Snell-Bergeron JK: Effect of Sitagliptin on Postprandial Glucagon and GLP-1 Levels In Patients With Type 1 Diabetes: Investigator-Initiated, Double-Blind, Randomized, Placebo- Controlled Trial. *Endocrine Practice*;19:19-28, 2013
48. Leslie J. **Klauff**, Ronald Brazg, Kristen Hughes, Ann M. Tideman, Holly C. Schachner, Patricia Stenger, Scott Pardo, Nancy Dunne, and Joan Lee Parkes: Accuracy Evaluation of Contour Next Compared with Five Blood Glucose Monitoring Systems Across a Wide Range of Blood Glucose Concentrations Occurring in a Clinical Research Setting. *Diabetes Technology & Therapeutics*, Volume 17, (1)8-15, 2015
49. Timothy Bailey, Jane F. Wallace, Carmine Green, Scott Pardo, Daniel Brown, Brian Pflug, Leslie J. **Klauff**: Accuracy and User Performance Evaluation of the Contour Next Link 2.4 Blood Glucose Monitoring System. *Clinica Chimaica Acta* 448:139-145, 2015
50. Timothy Bailey, Bruce W. Bode, Mark P. Christiansen, Leslie J. **Klauff**, Shridhara Alva: The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. *Diabetes Technology & Therapeutics*, Volume 17, Number 11, 2015
51. Ronald L. Brazg, MD, Leslie J. **Klauff**, MD and Allen M. Sussman, MD New Generation Guide Blood Glucose Monitoring System Exceeds International Accuracy Standards. *Journal of Diabetes Science and Technology*; 2016
52. Mark P. Christiansen, MD, Leslie J. **Klauff**, MD, PhD, Ron Brazg, MD, Anna R. Chang, MD, Carol J. Levy, MD, David Lam, MD, Douglas S. Denham, DO, George Atiee, MD, Bruce W. Bode, MD, Steven J. Walters, MS, Lynne Kelley, MD, and Timothy S. Bailey, MD. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. *Diabetes Technology & Therapeutics*, Volume 20, Number 3, 2018
53. Halis Kaan Akturk, MD, Janet K. Snell-Bergeson, PhD, Amanda Rewers, MD, Leslie J. **Klauff**, MD, PhD, Bruce W. Bode, MD, Anne L. Peters, MD, Timothy S. Bailey, MD, Satish K. Garg, MD. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared With Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. *Diabetes Technology & Therapeutics*, Volume 20, Number 10, 2018
54. Christiansen MP, **Klauff** LJ, Bailey TS, Brazg R, Carlson G, Tweden KS. A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study. *Diabetes Technology & Therapeutics* 2019 May;21(5):231-237.
55. William D. Arnold, PhD, Kenneth Kupfer, PhD, Monica Hvidsten Swensen, MSc, Kyle S. Fortner, BS, Harold J. **Klauff**, PhD, Richard C. San George, PhD. Fingerstick Precision and Total Error of a Point-of-Care HbA1c Test. *Journal of Diabetes Science and Technology* 2020, Volume 14(5) 890-895
56. Leslie **Klauff**, MD, Dachuang Cao, PhD, Mary Anne Dellva, PhD, Janet Tobian, MD, Junnosuke Miura, MD, Dominik Dahl, MD, Jean Lucas, MD, Juliana Bue-Valleskey, MS. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study. *Diabetes Obesity Metabolism*, 2020, Volume 22 1799-1807

BOOKS, CHAPTERS, EDITORIALS, & EDUCATIONAL PUBLICATIONS

(NON-PEER REVIEWED)

1. **Klaff LJ**, Sheppard M, Hudson AM, Tyler M, and Vinik AI: Cholecystokinin-octapeptide-like immunoreactivity in rat central nervous system. In: *Neuropeptides, Biochemical & Physiological Studies*, edited by RP Millar. Churchill Livingstone, Edinburgh, 1981, pp 87-96.
2. **Klaff LJ**, Vinik AI, and Heldsinger A: Acid secretagogue potencies and interactions in the activation of carbonic anhydrase in guinea pig parietal cells. In: *Neuropeptides, Biochemical & Physiological Studies*, edited by RP Millar. Churchill Livingstone, Edinburgh, 1981, pp 336-343.
3. **Klaff LJ**, Kernoff L, Vinik AI, Jackson WPU, Jacobs P: Sulphonylureas and platelet function. In: *Diabetes Mellitus*, edited by JS Skyler and GF Cahill Jr. Yorke Medical Books, USA, 1981, pp 152-155.
4. Millar RP, **Klaff LJ**, and Barron JL: The new hypothalamic releasing factors (editorial). *S Afr Med J* 62:924-925, 1982.
5. **Klaff LJ** and Sive AA: Continuous subcutaneous insulin infusion (editorial). *S Afr Med J* 63:61-62, 1983.
6. Guest Editor, *South African Journal of Continuing Medical Education*, Vol 1, No 3, 1983. Subject: Diabetes Mellitus. (a) Kahn SE and **Klaff LJ**: The importance of metabolic control in diabetes mellitus, pp 15-23. (b) **Klaff LJ** and Sive AA: Factors in the genesis of diabetes mellitus, pp 80-84.
7. Clinical Discussant, Clinicopathological Conference. Post-abortal fever and shock. *S Afr Med J* 63:444-447, 1983.
8. **Klaff LJ**: Computer program. Diabetes mellitus: an update on outpatient evaluation and management 1985. CME Inc. and University of Washington, Seattle.
9. **Klaff LJ** and Palmer JP: Risk for developing cardiovascular risk factor: glucose intolerance. In: *Cardiology clinics: risk for developing cardiovascular risk factors and adverse effects of risk factor reduction*, edited by FH Messerlio and C Amodeo. W.B. Saunders Co., Philadelphia, 1986, pp 67-73.